Ascendis Pharma A/S

ASND · NASDAQ

$243.37+$0.38 (+0.16%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $242.99

ASND analyst rating

BuyConsensus of 18 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy18
Hold0
Underperform0
Sell0

12-month price target · 24 analysts

Average $319.29 (+31.2% upside)

Low: $271.69
Now: $243.37
High: $378.00

Upgrades and downgrades

The latest rating actions, newest first

ASND analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
UBS	Oct 15, 2026	Initiates	Buy	$307.00 → $269.00	67%
Cantor Fitzgerald	Sep 25, 2026	Maintains	Overweight	$300.00	51%
Raymond James	Sep 15, 2026	Downgrade	Strong Buy → Outperform	$287.00	60%
Oppenheimer	Sep 2, 2026	Maintains	Outperform	$304.00 → $312.00	46%
Morgan Stanley	Sep 1, 2026	Maintains	Overweight	$275.00 → $273.00	36%
Wedbush	Sep 1, 2026	Maintains	Outperform	$327.00	40%
B of A Securities	Aug 31, 2026	Maintains	Buy	$306.00 → $304.00	46%
Jefferies	Aug 31, 2026	Maintains	Buy	$333.00 → $330.00	41%
Stifel	Aug 31, 2026	Maintains	Buy	$328.00 → $326.00	59%
HC Wainwright & Co.	Aug 31, 2026	Maintains	Buy	$345.00 → $344.00	31%

The case for and against

Updated Oct 18, 2026

Bull case

Ascendis Pharma is compelling because its TransCon platform now supports three commercial growth engines, with YORVIPATH driving current revenue, SKYTROFA providing a stable base, and YUVIWEL adding a differentiated weekly achondroplasia option that improves convenience versus daily injections. YUVIWEL’s early U.S. launch has surpassed 220 unique patient enrollments across more than 100 prescribers with over 65% reimbursement approval, while YORVIPATH revenue reached €252 million in 2Q26 and the company reported €812 million in cash and cash equivalents as of June 30, 2026. Beyond commercialization, durable 78-week COACH data, planned Phase 3 starts in 2H26 and 4Q26, and expected operating leverage from a lean cost base support a credible path to sustained revenue and cash-flow growth.

Bear case

Ascendis Pharma is a commercial and clinical-stage biotechnology company exposed to meaningful execution risk across clinical readouts, regulatory uncertainty, manufacturing, competition, and litigation, all of which can impair confidence in its TransCon platform. Although 2Q26 showed commercial momentum with YORVIPATH up ~26% Q/Q, SKYTROFA up ~24%, and YUVIWEL contributing its first ~$8.8M, the business still faces heavy reliance on U.S. uptake, reimbursement, and durable patient persistence. Its negative outlook is reinforced by the upcoming ITC decision, the Dec. 21 Commission decision, and the risk that adverse confirmatory data, label restrictions, pricing pressure, or patent-related import limits could curb growth and operating leverage.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.